Valeant gets additional notices of default from bondholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/22/2026
- Wall St ends higher on chip stocks recovery; earnings in focus
- Oil prices rise to five-week high on US-Iran attacks, Houthi blockade threat
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- Emirates refusing to take delivery of first 10 Boeing 777X jets
- Wall St ends higher on chip stocks recovery; earnings in focus
- Palo Alto Networks to acquire Embrace to expand observability tools
- Myriad Genetics launches four-in-one prenatal genetic screen
Valeant Pharma (VRX) Appoints Joseph Papa as CEO
April 25, 2016 8:38 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that its Board of Directors has named Joseph C. Papa to become Valeant's Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. Mr. Papa will join Valeant from Perrigo Company plc, a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as Chairman and Chief Executive Officer. Mr. Papa, who will also join Valeant's Board of Directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a... More
Valeant Pharma (VRX) Announces Receipt of Additional Notice of Default Due to Delay of 10-K Filing
April 25, 2016 6:28 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that, as a result of the delay in the Company filing its Form 10-K for the fiscal year ended December 31, 2015 (the "Form 10-K"), it has received notices of default from the trustee under the indentures governing its 5.375% Senior Notes due... More
